(Z)-2-(3,4-Dichlorophenyl)-3-(1H-Pyrrol-2-yl)Acrylonitrile Exhibits Selective Antitumor Activity in Breast Cancer Cell Lines via the Aryl Hydrocarbon Receptor Pathway.

Saved in:
Bibliographic Details
Title: (Z)-2-(3,4-Dichlorophenyl)-3-(1H-Pyrrol-2-yl)Acrylonitrile Exhibits Selective Antitumor Activity in Breast Cancer Cell Lines via the Aryl Hydrocarbon Receptor Pathway.
Authors: Gilbert J; Experimental Therapeutics Group, Department of Medical Oncology, Calvary Mater Newcastle Hospital, Waratah, New South Wales, Australia (J.G., J.A.S.); and Priority Research Centre for Reproductive Science, Faculty of Science (G.N.D.I.), and Chemistry, School of Environmental and Life Sciences, Faculty of Science (M.T., A.M., J.A.S.), University of Newcastle, Callaghan, New South Wales, Australia., De Iuliis GN; Experimental Therapeutics Group, Department of Medical Oncology, Calvary Mater Newcastle Hospital, Waratah, New South Wales, Australia (J.G., J.A.S.); and Priority Research Centre for Reproductive Science, Faculty of Science (G.N.D.I.), and Chemistry, School of Environmental and Life Sciences, Faculty of Science (M.T., A.M., J.A.S.), University of Newcastle, Callaghan, New South Wales, Australia., Tarleton M; Experimental Therapeutics Group, Department of Medical Oncology, Calvary Mater Newcastle Hospital, Waratah, New South Wales, Australia (J.G., J.A.S.); and Priority Research Centre for Reproductive Science, Faculty of Science (G.N.D.I.), and Chemistry, School of Environmental and Life Sciences, Faculty of Science (M.T., A.M., J.A.S.), University of Newcastle, Callaghan, New South Wales, Australia., McCluskey A; Experimental Therapeutics Group, Department of Medical Oncology, Calvary Mater Newcastle Hospital, Waratah, New South Wales, Australia (J.G., J.A.S.); and Priority Research Centre for Reproductive Science, Faculty of Science (G.N.D.I.), and Chemistry, School of Environmental and Life Sciences, Faculty of Science (M.T., A.M., J.A.S.), University of Newcastle, Callaghan, New South Wales, Australia., Sakoff JA; Experimental Therapeutics Group, Department of Medical Oncology, Calvary Mater Newcastle Hospital, Waratah, New South Wales, Australia (J.G., J.A.S.); and Priority Research Centre for Reproductive Science, Faculty of Science (G.N.D.I.), and Chemistry, School of Environmental and Life Sciences, Faculty of Science (M.T., A.M., J.A.S.), University of Newcastle, Callaghan, New South Wales, Australia jennette.sakoff@newcastle.edu.au.
Source: Molecular pharmacology [Mol Pharmacol] 2018 Feb; Vol. 93 (2), pp. 168-177. Date of Electronic Publication: 2017 Dec 21.
Publication Type: Journal Article; Research Support, Non-U.S. Gov't
Journal Info: Publisher: Elsevier Country of Publication: Netherlands NLM ID: 0035623 Publication Model: Print-Electronic Cited Medium: Internet ISSN: 1521-0111 (Electronic) Linking ISSN: 0026895X NLM ISO Abbreviation: Mol Pharmacol Subsets: MEDLINE
Database: MEDLINE Ultimate
Description
ISSN:1521-0111
DOI:10.1124/mol.117.109827